[Chinese expert consensus on the multidisciplinary clinical diagnosis and treatment of stage Ⅲ non-small cell lung cancer (2019)].

Lung cancer is the most common cancer and the leading cause of cancer death in China, with 733 thousands estimated new lung cancer cases and 610 thousands deaths in 2015. In the pathological type of lung cancer, non-small cell lung cancer (NSCLC) accounts for 80%~85%, and 30% of NSCLC patients have already reached stage Ⅲ at diagnosis, who have lost the optimal opportunity for surgical treatment. Stage Ⅲ NSCLC is highly heterogeneous, the 5-year survival rates of stage ⅢA, ⅢB and ⅢC NSCLC are 36%, 26% and 13%, respectively. For the great complexity of making decisions in the clinical practice of stage Ⅲ NSCLC, the experts of this consensus group combine the latest clinical research results and cutting-edge multidisciplinary concepts, conduct in-depth and detailed discussions on the hot issues and controversies in the diagnosis, treatment and follow-up surveillance of stage Ⅲ NSCLC. Chinese Anti-Cancer Association and Committee of Lung Cancer Society jointly publish this consensus to provide guidance for Chinese clinicians.肺癌是我国发病率和死亡率最高的肿瘤，2015年我国新发肺癌病例约为73万，因肺癌死亡病例约为61万。在肺癌的病理类型中，非小细胞肺癌(NSCLC)占80%～85%，其中约30%的NSCLC患者在就诊时已达到Ⅲ期，大多失去最佳手术治疗时机。Ⅲ期NSCLC具有高度异质性，ⅢA期、ⅢB期和ⅢC期NSCLC的5年生存率分别为36%、26%和13%。Ⅲ期NSCLC患者在临床诊疗方案的选择方面具有复杂性，因此本共识专家组结合最新的临床研究结果和前沿的多学科诊疗理念，针对Ⅲ期NSCLC诊断、治疗和随访监测等多个方面的热点问题和争议内容进行了深入细致的探讨，中国抗癌协会肺癌专业委员会和中华医学会肿瘤学分会肺癌学组联合发布本共识，旨在为中国临床医师对NSCLC的临床实践提供指导。.